Sign in

You're signed outSign in or to get full access.

John Wolleben

Managing Director at JMP Securities

Jonathan Wolleben is a Managing Director at Citizens JMP (JMP Securities), specializing in equity research of early-stage and mid-cap healthcare and biotechnology companies. He covers firms including Madrigal Pharmaceuticals, Larimar Therapeutics, Pharvaris, Astria Therapeutics, Quince Therapeutics, Ocular Therapeutix, Crinetics Pharmaceuticals, and others. Wolleben’s performance metrics include a 4.4-star analyst rating on TipRanks, a historical success rate ranging from 45%–50%, and average returns exceeding +19% on several recommendations, with individual calls such as a +416% return for Madrigal Pharmaceuticals and a 104% profit on Ocular Therapeutix. His career at JMP Securities began in late 2016, progressing from Associate Biotech Analyst through Senior Associate, Vice President, Director, and Managing Director since February 2023; previously, he earned BS and MS degrees from Carnegie Mellon University focusing on biological sciences and biotechnology management. He is FINRA-registered and possesses key securities licenses required for equity research.

John Wolleben's questions to Sarepta Therapeutics (SRPT) leadership

Question · Q4 2025

John Wolleben requested context on the size of the Japanese market for ELEVIDYS, any notable ordering dynamics, and the potential for non-ambulatory patient treatment in Japan, including necessary additional activities.

Answer

Doug Ingram, President and Chief Executive Officer, described Japan as an extraordinary, high-value market with a large population and advanced healthcare system, expressing excitement for the opportunity to benefit Duchenne patients there. He deferred specific market size and ordering dynamics to Sarepta's partner, Roche, who is launching the therapy in Japan.

Ask follow-up questions

Fintool

Fintool can predict Sarepta Therapeutics logo SRPT's earnings beat/miss a week before the call

John Wolleben's questions to MADRIGAL PHARMACEUTICALS (MDGL) leadership

Question · Q3 2024

An analyst on behalf of John Wolleben asked how payers are currently managing patients on both GLP-1 therapies and Rezdiffra, and how this might predict future dynamics if a GLP-1 is approved for NASH.

Answer

CEO William Sibold estimated that approximately 25% of Rezdiffra patients are concurrently using a GLP-1 for comorbidities, with market research suggesting up to 50% have prior exposure. He explained that physicians are treating NASH as a distinct condition requiring Rezdiffra, regardless of a patient's GLP-1 history, which he believes positions the company strongly for any future market changes.

Ask follow-up questions

Fintool

Fintool can predict MADRIGAL PHARMACEUTICALS logo MDGL's earnings beat/miss a week before the call

News for Covered Companies

Rezdiffra Hits $958M in Year One — But Madrigal Stock Drops 11%

Rezdiffra Hits $958M in Year One — But Madrigal Stock Drops 11%

MDGLFeb 19
Sarepta's ELEVIDYS Shows 70%+ Disease Slowing at 3 Years—Stock Surges 13% on Redemption Data

Sarepta's ELEVIDYS Shows 70%+ Disease Slowing at 3 Years—Stock Surges 13% on Redemption Data

SRPTJan 26